![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Dry powder, micronised formulations of a single peptidic VLA-4 antagonist are claimed. Their use is claimed to provide a method of treating asthma and other inflammatory diseases when administered via inhalation. The active ingredient of these formulations is deduced to be the clinical candidate GW-559090.